Top Page
BioArctic AB Class B
(Frankfurt:BIOA.B)
BioArctic AB Class B (BIOA.B) vs. iShares MSCI Sweden ETF (EWD)
BioArctic AB Class B Business Overview & Revenue Model
BioArctic AB Class B Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86B | 257.35M | 616.00M | 228.29M | 23.15M | 62.35M |
| Gross Profit | 1.81B | 230.37M | 526.37M | 153.97M | -31.92M | 12.11M |
| EBITDA | 1.21B | -165.13M | 295.29M | 4.22M | -126.42M | -74.58M |
| Net Income | 1.07B | -177.08M | 229.25M | -11.18M | -119.79M | -68.52M |
Balance Sheet | ||||||
| Total Assets | 2.33B | 1.11B | 1.19B | 858.31M | 897.73M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92B | 778.92M | 1.11B | 805.39M | 848.40M | 999.94M |
| Total Debt | 48.99M | 54.23M | 4.98M | 10.04M | 15.88M | 20.77M |
| Total Liabilities | 293.59M | 216.74M | 139.50M | 72.06M | 109.05M | 143.01M |
| Stockholders Equity | 2.04B | 894.94M | 1.05B | 786.24M | 788.68M | 907.30M |
Cash Flow | ||||||
| Free Cash Flow | 1.05B | -342.97M | 302.25M | -44.38M | -144.84M | -104.81M |
| Operating Cash Flow | 1.05B | -316.33M | 309.69M | -31.64M | -140.46M | -92.34M |
| Investing Cash Flow | -584.08M | 205.63M | -507.49M | -12.76M | -4.41M | -12.52M |
| Financing Cash Flow | 18.00M | 5.69M | 14.06M | -2.81M | -7.39M | -6.60M |
BioArctic AB Class B Technical Analysis
BioArctic AB Class B Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €27.75B | 25.99 | 72.22% | ― | 521.22% | ― | |
54 Neutral | kr3.34B | ― | ― | ― | 20.12% | 40.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €2.51B | ― | -41.54% | ― | ― | 0.57% | |
45 Neutral | €2.89B | ― | -55.23% | ― | -92.57% | -7.72% | |
41 Neutral | $1.78B | ― | -28.70% | ― | 382.81% | 23.87% | |
31 Underperform | €658.82M | ― | -275.87% | ― | ― | 38.99% |
BioArctic AB Class B Corporate Events
BioArctic AB announced that sales of Leqembi® totaled 23.1 billion yen in the second quarter of 2025, resulting in a significant royalty increase of approximately 280% compared to the previous year. The sales figures included a one-time stockpiling effect in China due to tariff risks, with global sales excluding this effect amounting to 17.8 billion yen. This financial performance underscores BioArctic’s strengthened market position and potential for future growth in the Alzheimer’s treatment sector.
BioArctic AB’s partner, Eisai, presented new data at the Alzheimer’s Association International Conference 2025, highlighting the efficacy and safety of lecanemab in treating early-stage Alzheimer’s disease. The findings from the phase 3 Clarity AD study and real-world evidence suggest that lecanemab can slow disease progression and maintain cognitive function over four years, with a consistent safety profile, offering promising long-term benefits for patients.
BioArctic AB’s partner Eisai will present four-year efficacy and safety data on lecanemab, a treatment for early Alzheimer’s disease, at the Alzheimer’s Association International Conference 2025. The presentation will include findings on a subcutaneous formulation for maintenance dosing and real-world case studies, highlighting the drug’s potential impact on treatment protocols and its ongoing development in collaboration with Biogen. BioArctic is preparing for joint commercialization of lecanemab in the Nordic region, emphasizing its strategic focus on expanding access to innovative Alzheimer’s treatments.
BioArctic AB’s partner Eisai announced that their co-developed Alzheimer’s drug, lecanemab (Leqembi®), has been awarded the 9th Bioindustry Award by the Japan Bioindustry Association. This recognition highlights the significance of lecanemab in altering the course of Alzheimer’s disease by targeting amyloid-beta proteins. Eisai leads the global development and commercialization efforts, with BioArctic having rights to commercialize in the Nordic region, indicating a strong market positioning and potential impact on stakeholders in the biopharmaceutical industry.
BioArctic AB announced that its founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his groundbreaking work in Alzheimer’s research and the development of lecanemab. This recognition highlights BioArctic’s significant contributions to the field and underscores the potential impact of lecanemab in altering the course of Alzheimer’s disease, marking a paradigm shift in treatment possibilities.
BioArctic AB announced the initiation of the next cohorts in its Phase 2a study of exidavnemab following a positive interim safety review. Exidavnemab, a monoclonal antibody targeting pathological alpha-synuclein aggregates, is being developed as a treatment for Parkinson’s disease and Multiple System Atrophy (MSA). The study’s progression to higher doses marks a significant step in addressing the unmet medical need for disease-modifying treatments in synucleinopathies. Exidavnemab has received orphan drug designation in the US and a positive opinion in the EU for MSA treatment, highlighting its potential impact on the company’s operations and industry positioning.
BioArctic AB held its Capital Markets Day 2025, outlining its strategic goals for 2030, which include expanding its pipeline, forming global partnerships, and launching Leqembi® for Alzheimer’s in the Nordics. The company aims to leverage its strong financial position, innovative research platforms, and successful partnerships to drive growth and profitability, positioning itself as a leading pharmaceutical entity in Sweden.
BioArctic AB announced the issuance of 3,000 Class B shares as part of its 2019/2028 stock option program, bringing the total number of shares to 88,531,485. This move reflects the company’s ongoing commitment to rewarding its stakeholders and maintaining a robust capital structure, with implications for its market positioning and shareholder engagement.
At its Annual General Meeting, BioArctic AB resolved to carry forward SEK 889,598,575 without paying dividends for 2024, re-elected its board members, and approved remuneration for them. The meeting also authorized the board to issue new shares and introduced a three-year incentive program for employees, which includes performance-based share units contingent on meeting specific conditions related to shareholder returns, operational targets, and sustainability goals.
BioArctic AB has received a positive opinion from the European Medicines Agency for orphan medicinal product designation for exidavnemab, a treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease. This designation provides incentives for developing treatments for rare diseases, potentially enhancing BioArctic’s market positioning and offering hope for addressing high unmet medical needs in MSA and related disorders.
BioArctic AB reported significant financial growth in Q1 2025, driven by the approval and commercial success of its Alzheimer’s treatment, Leqembi, in the EU and other markets. The company also benefited from a lucrative license agreement with Bristol Myers Squibb, contributing to a substantial increase in net revenues and operating profit, positioning BioArctic as a key player in the neurodegenerative disease treatment market.
Eisai, in partnership with BioArctic, projects significant revenue growth for their Alzheimer’s treatment, Leqembi, with sales expected to reach JPY 76.5 billion for fiscal year 2025. This growth reflects a 73% increase from the previous year, generating substantial royalties for BioArctic and strengthening their market position in Alzheimer’s treatment.
BioArctic AB will release its first quarter report for 2025 on May 21, inviting investors, analysts, and media to an audiocast and teleconference where the CEO and CFO will present and discuss the results. This event reflects BioArctic’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market perception and investor relations.
BioArctic AB has expanded its Phase 2a EXIST study to include Multiple System Atrophy (MSA) patients, following regulatory approval in Spain and Poland. This expansion marks a significant step in developing exidavnemab, a monoclonal antibody targeting alpha-synuclein aggregates, as a potential treatment for MSA and Parkinson’s, addressing a high unmet medical need in neurodegenerative diseases.